Brooksville, FL (PRWEB) April 17, 2012
The Federal Drug Administration this week completed its inspection of TG United Inc., clearing the way for the Brooksville, Florida pharmaceutical manufacturer to begin a long-awaited expansion, Chief Executive David Daniel Ambrose said today.
The FDA has not yet released the results of its routine inspection, which has been ongoing since January, but the CEO said he was expecting “a clean bill of health” – and when it arrives, TG United Inc. will begin purchasing new drug applications from other pharmaceuticals manufacturers, David Daniel Ambrose said.
Specifically, TG United Inc. will be looking for Abbreviated New Drug Applications submitted to the FDA by other manufacturers. The ANDAs, David Daniel Ambrose noted, are shorter than standard New Drug Applications and represent a faster growth curve for TG United Inc.
The chief executive would not reveal which specific products or industries TG United Inc. was considering, though he did indicate his company would be an aggressive bidder. “We’ll be looking to purchase ANDAs from anywhere we can get our hands on them,” David Daniel Ambrose said. “This is how we plan our growing. This is what takes us to the next level.”
The completion of the FDA inspection coincides with the launch of TG United’s new website at tgunited.com. After several months of development, David Daniel Ambrose noted, the site will offer a comprehensive list of TG United Inc.’s products, updates on the latest developments in its state-of-the-art laboratory, information on job openings and general news about the pharmaceutical industry.
“This is an exciting time for our companies,” David Daniel Ambrose said. “Growth is always exciting, and the launch of our new website is the perfect illustration of our mission to expand and provide new and better services to our clients and industry partners.”
“Things are going to happen fast,” noted TG United Inc. employee Daniel Dean, who helped developed the new website. “David Daniel Ambrose is an aggressive CEO who doesn’t like to waste time when it comes to growth and expansion. He gets an idea, fine-tunes it and puts it into effect with confidence, and that’s exactly what he’s doing with this new ANDA strategy.”
David Daniel Ambrose brings over 15 years of industry experience to TG United Inc. He’s also the CEO of MCR American Pharmaceuticals, a distribution company he bought in 1999 just two years after joining its sales team, and is the founder and chief executive of generic pharmaceuticals provider Ambi Pharmaceuticals. He launched TG United Inc. in 2004 and sold both TG United and Ambi to Neural High-Tech Pharmaceuticals in 2008, shortly before taking over as Neural High-Tech’s chairman and chief executive.
MCR American Pharmaceuticals’ brand-name product line includes the 20-product family of Maxiphen and Maxifed expectorants/decongestants.
The FDA inspection covered the Brooksville campus containing all of David Daniel Ambrose’s companies. Even though “the FDA’s job is making sure they find something you can improve,” the CEO expects a glowing report – and expects to start expanding TG United Inc. product line soon.
“We’ll start moving forward in April,” David Daniel Ambrose said. “This company is positioned to move forward dramatically in 2012, and the time is now. Purchasing these ANDAs is the key source of our future growth.”
About David Daniel Ambrose
David Daniel Ambrose is a pharmaceutical company chief executive with more than 15 years of industry experience. David Ambrose is the CEO of MCR American Pharmaceuticals and TG United Inc, as well as parent company Neural High-Tech Pharmaceuticals, all based on Brooksville, Florida. David Daniel Ambrose received a bachelor’s degree in finance from West Virginia University in 1990 and lives in Brooksville with his wife of 18 years, Amanda, and their three children.